Literature DB >> 7916059

Involvement of human leukocyte antigen class I molecules in human immunodeficiency virus infection of CD4-positive cells.

M Benkirane1, D Blanc-Zouaoui, M Hirn, C Devaux.   

Abstract

We have studied the putative roles of human immunodeficiency virus (HIV)-associated and cell surface-expressed major histocompatibility complex class I (MHC-I) molecules in the course of the HIV life cycle by the combined use of MHC-I molecule-positive and MHC-I molecule-negative virus particles and MHC-I molecule-positive and MHC-I molecule-negative CD4+ human cells. We found (i) that several anti-MHC-I monoclonal antibodies neutralize cell infection by direct interaction with HIV-associated MHC-I antigens, (ii) that these HIV-associated MHC-I antigens are however dispensable for cell infection, and (iii) that the cell surface-expressed MHC-I molecules are unnecessary for productive infection of CD4+ human cells. These results clarify further the functions of MHC-I molecules during the HIV life cycle.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7916059      PMCID: PMC237054     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus.

Authors:  C Stahl-Hennig; G Voss; U Dittmer; C Coulibaly; H Petry; B Makoschey; M P Cranage; A M Aubertin; W Lüke; G Hunsmann
Journal:  AIDS       Date:  1993-06       Impact factor: 4.177

2.  Subtyping of human immunodeficiency virus isolates with a panel of monoclonal antibodies: identification of conserved and divergent epitopes on p17 and p25 core proteins.

Authors:  V Robert-Hebmann; S Emiliani; M Resnicoff; F Jean; C Devaux
Journal:  Mol Immunol       Date:  1992-10       Impact factor: 4.407

3.  Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus.

Authors:  G T Spear; D M Takefman; B L Sullivan; A L Landay; M B Jennings; J R Carlson
Journal:  Virology       Date:  1993-08       Impact factor: 3.616

4.  Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines.

Authors:  L O Arthur; J W Bess; R C Sowder; R E Benveniste; D L Mann; J C Chermann; L E Henderson
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

5.  Clonal analysis of murine B cell response to the human immunodeficiency virus type 1 (HIV1)-gag p17 and p25 antigens.

Authors:  V Robert-Hebmann; S Emiliani; F Jean; M Resnicoff; F Traincard; C Devaux
Journal:  Mol Immunol       Date:  1992-06       Impact factor: 4.407

6.  A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells.

Authors:  J P Moore; Q J Sattentau; P J Klasse; L C Burkly
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 gp120 C5 region mimics the HLA class I alpha 1 peptide-binding domain.

Authors:  L Lopalco; C De Santis; R Meneveri; R Longhi; E Ginelli; F Grassi; A G Siccardi; A Beretta
Journal:  Eur J Immunol       Date:  1993-08       Impact factor: 5.532

8.  The monoclonal CD4 antibody M-T413 inhibits cellular infection with human immunodeficiency virus after viral attachment to the cell membrane: an approach to postexposure prophylaxis.

Authors:  E P Rieber; C Federle; C Reiter; S Krauss; L Gürtler; J Eberle; F Deinhardt; G Riethmüller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

9.  Ig CDR3-like region of the CD4 molecule is involved in HIV-induced syncytia formation but not in viral entry.

Authors:  P Corbeau; M Benkirane; R Weil; C David; S Emiliani; D Olive; C Mawas; A Serre; C Devaux
Journal:  J Immunol       Date:  1993-01-01       Impact factor: 5.422

10.  Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response.

Authors:  W L Chan; A Rodgers; R D Hancock; F Taffs; P Kitchin; G Farrar; F Y Liew
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

View more
  9 in total

1.  Binding of human immunodeficiency virus type 1 to CD4 induces association of Lck and Raf-1 and activates Raf-1 by a Ras-independent pathway.

Authors:  W Popik; P M Pitha
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

2.  Inhibition of human immunodeficiency virus type 1 production in infected peripheral blood mononuclear cells by human leukocyte antigen class I-specific antibodies: evidence for a novel antiviral mechanism.

Authors:  L Briant; M Benkirane; M Girard; M Hirn; C Iosef; C Devaux
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

3.  T cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM-1.

Authors:  J F Fortin; R Cantin; M J Tremblay
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

4.  Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity.

Authors:  J F Fortin; R Cantin; G Lamontagne; M Tremblay
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo.

Authors:  Salim Bounou; Jacques E Leclerc; Michel J Tremblay
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

6.  The cytoplasmic tail of CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3-like region in domain 1 of CD4.

Authors:  M Benkirane; H Schmid-Antomarchi; D R Littman; M Hirn; B Rossi; C Devaux
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Level of ICAM-1 surface expression on virus producer cells influences both the amount of virion-bound host ICAM-1 and human immunodeficiency virus type 1 infectivity.

Authors:  J S Paquette; J F Fortin; L Blanchard; M J Tremblay
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

8.  The cytoplasmic domain of CD4 plays a critical role during the early stages of HIV infection in T-cells.

Authors:  M Benkirane; K T Jeang; C Devaux
Journal:  EMBO J       Date:  1994-12-01       Impact factor: 11.598

9.  Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.

Authors:  M Saifuddin; C J Parker; M E Peeples; M K Gorny; S Zolla-Pazner; M Ghassemi; I A Rooney; J P Atkinson; G T Spear
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.